Increased levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients with active pulmonary sarcoidosis

Autor: Mroz RM, Korniluk M, Stasiak-Barmuta A, Ossolinska M, Chyczewska E

Publikováno v: European Journal of Medical Research, Vol 14, Iss Suppl 4, Pp 165-169 (2009)

Abstract Objective It has recently been described that circulatory and BAL regulatory T-cells (Tregs), defined as CD4+CD25highCD127low are increased in patients with active sarcoidosis compared with other interstitial lung diseases. Materials and met

Externí odkaz: https://doaj.org/article/9f835388bad94645b97350ee53167665

Dermatomyositis masquerading as pulmonary embolism

Autor: Mroz RM, Korniluk M, Chyczewska E

Publikováno v: European Journal of Medical Research, Vol 14, Iss Suppl 4, Pp 162-164 (2009)

Abstract A 61-year-old Caucasian was admitted to Department of Chest Diseases and Tuberculosis, Medical University of Bialystok, Poland for progressive muscle weakness and weight loss. Eighteen months prior to admission, the patient had been diagnose

Externí odkaz: https://doaj.org/article/2b714af4ecec45aa90c18075f357d8d8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.

Autor: Watz H; Velocity Clinical Research Grosshansdorf, Airway Research Center North (ARCN), Formerly Pulmonary Research Institute at Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Wöhrendamm 80, 22927, Grosshansdorf, Germany. h.watz@pulmoresearch.de., Kirsten AM; Velocity Clinical Research Grosshansdorf, Airway Research Center North (ARCN), Formerly Pulmonary Research Institute at Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Wöhrendamm 80, 22927, Grosshansdorf, Germany., Ludwig-Sengpiel A; Velocity Clinical Research Lübeck, Formerly KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany., Krüll M; Institut für Allergie-und Asthmaforschung Berlin, IAAB, Berlin, Germany., Mroz RM; Second Department of Lung Diseases, Lung Cancer and Internal Diseases, Bialystok Medical University, Bialystok, Poland., Georges G; Global Clinical Development, Chiesi USA Inc, Cary, NC, USA., Varoli G; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy., Charretier R; Global Clinical Development, Chiesi SAS, Paris, France., Cortellini M; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy., Vele A; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy., Galkin D; Global Clinical Development, Chiesi USA Inc, Cary, NC, USA.

Publikováno v: Respiratory research [Respir Res] 2024 Oct 17; Vol. 25 (1), pp. 378. Date of Electronic Publication: 2024 Oct 17.

Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study.

Autor: Crapo JD; Department of Medicine, National Jewish Health, Denver, CO, USA. crapoj@njhealth.org., Gupta A; TA Inflammation Medicine, Boehringer Ingelheim International GmbH, Biberach an Der Riss, Germany., Lynch DA; Department of Radiology, National Jewish Health, Denver, CO, USA., Turner AM; Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Mroz RM; 2nd Department of Lung Diseases and Tuberculosis, Bialystok Medical University, Bialystok, Poland., Janssens W; Department of Chronic Diseases and Metabolism (CHROMETA), Laboratory of Respiratory Diseases and Thoracic Surgery (BREATH), University Hospital Leuven, Louvain, KU, Belgium., Ludwig-Sengpiel A; KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany., Koegler H; TA Inflammation Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany., Eleftheraki A; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany., Risse F; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany., Diefenbach C; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany.

Publikováno v: Respiratory research [Respir Res] 2023 Nov 17; Vol. 24 (1), pp. 290. Date of Electronic Publication: 2023 Nov 17.